Mereo BioPharma Group Plc develops therapeutics for oncology and rare diseases, focusing on setrusumab for osteogenesis imperfecta and alvelestat for alpha-1-antitrypsin deficiency. The company also has oncology candidates and partnered programs like Navicixizumab.
Christine Ann Fox sold 9,128 shares of MREO on 12 September at $4.47 per share, worth a total of $41K. They now own 108,443 MREO shares, or a 8% holding decrease.
📡️ Health Care
Insider Trades
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
